Vaccinex, Inc. is a clinical-stage biotechnology company headquartered in Rochester, New York, dedicated to developing novel therapies for patients with cancer and neurodegenerative diseases. The company leverages its proprietary Signal leopard (S-L) antibody engineering platform to discover and develop monoclonal antibodies that target key signaling pathways involved in disease progression. [1]
| Attribute | Details | [2]
|-----------|---------|
| Headquarters | Rochester, New York, USA |
| Founded | 1997 |
| Ticker | VCNX (NASDAQ) |
| Focus Areas | Neurodegenerative diseases, Cancer |
| Platform | ActivMAb® antibody discovery |
Pepinemab is a humanized monoclonal IgG4 antibody that binds and blocks SEMA4D signaling. It is currently under investigation for both neurological and oncology applications. SEMA4D is an extracellular signaling molecule that regulates immune and inflammatory cell migration and activation, playing roles in tumor immune evasion and neuroinflammation.
SIGNAL — Huntington's Disease Trial (Completed 2020/2021):
The company's initial neurodegenerative focus was Huntington's disease, where the Phase 2 SIGNAL trial was completed. This trial evaluated the safety and efficacy of pepinemab in patients with early to mid-stage Huntington's disease.
SIGNAL-AD — Alzheimer's Disease Trial:
Vaccinex has advanced pepinemab into a Phase 1b/2 trial for Alzheimer's disease (SIGNAL-AD), investigating the role of SEMA4D inhibition in reducing neuroinflammation and preserving cognitive function. Positive topline data from this trial indicated cognitive benefit.
December 2025 Development:
The company announced a "$60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer's Disease," representing a significant investment in advancing this program toward later-stage clinical development.
The company previously investigated VX-15 in Parkinson's disease, focusing on its potential to modify disease progression through modulation of neuroinflammation. While the PD program appears to have been deprioritized in favor of AD and HD, the SEMA4D mechanism remains relevant to PD pathology as documented in the scientific literature.
Semaphorin 4D (SEMA4D) is a transmembrane signaling molecule that plays complex roles in neuroinflammation and neural repair. The protein is expressed by activated microglia and infiltrating immune cells in the central nervous system^3.
Pro-inflammatory Effects:
Therapeutic Rationale:
Plexin-B1 Interactions:
SEMA4D signals through Plexin-B1 receptors on neurons and oligodendrocytes, as well as through CD72 on immune cells. The Plexin-B1 pathway is implicated in regulating cytoskeletal dynamics, cell migration, and inflammatory responses^4.
The SIGNAL trial was Vaccinex's initial Phase 2 clinical program in neurodegeneration, evaluating pepinemab in patients with early to mid-stage Huntington's disease. This trial was designed to assess the safety, tolerability, and efficacy of the anti-SEMA4D antibody in modifying disease progression.
Trial Design:
Rationale for HD:
Huntington's disease involves significant neuroinflammation driven by mutant huntingtin protein. SEMA4D is upregulated in HD models and patient samples, suggesting that blocking this signaling pathway could reduce microglial activation and inflammatory damage to neurons.
The SIGNAL-AD trial represents Vaccinex's current focus in neurodegeneration. This Phase 1b/2 trial investigates pepinemab in patients with early to moderate Alzheimer's disease.
Trial Rationale:
Key Findings:
The December 2025 financing agreement ($60 million) specifically supports advancement to a Phase 2b trial, representing a significant investment in this program.
Given the role of neuroinflammation across neurodegenerative conditions, pepinemab has potential applications beyond HD and AD:
| Indication | Rationale | Development Status |
|---|---|---|
| Multiple System Atrophy | SEMA4D in oligodendrocyte dysfunction | Research stage |
| Parkinson's Disease | Microglial activation, neuroinflammation | Previously investigated, not currently active |
| Amyotrophic Lateral Sclerosis | Neuroinflammation in motor neurons | Preclinical exploration |
Safety Profile:
Efficacy Signals:
Vaccinex has additional preclinical programs targeting other mechanisms involved in neurodegenerative processes, including:
The company's expertise in SEMA4D biology provides a foundation for developing next-generation therapeutics that build on the clinical validation achieved with pepinemab.
Vaccinex has also developed antibodies targeting SEMA4D for oncology applications, recognizing the role of SEMA4D in tumor immunity and metastasis.
KEYNOTE-B84 — Phase 2 trial in recurrent/metastatic head and neck squamous cell carcinoma (combined with pembrolizumab)
Phase 1b/2 — Non-small cell lung cancer (combined with avelumab)
The company's immuno-oncology strategy leverages SEMA4D's role in regulating immune cell trafficking and activation within the tumor microenvironment.
Vaccinex leveraged its proprietary ActivMAb® discovery platform for antibody generation against complex multipass membrane proteins (GPCRs, ion channels). The platform enables rapid selection of high-affinity human monoclonal antibodies.
Vaccinex has collaborated with academic institutions and pharmaceutical companies to advance its pipeline, including partnerships focused on understanding the role of Sema4D in neurodegeneration.
Vaccinex operates in the neuroinflammation therapeutic space with several competitors targeting different mechanisms:
| Company | Drug | Target | Mechanism | Status |
|---|---|---|---|---|
| Biogen | BIIB122 | LRRK2 | Kinase inhibitor | Phase 2 |
| Roche | Gantenerumab | Amyloid-β | Monoclonal antibody | Phase 3 |
| Prothelia | Protollin | TLR2/4 | Immunomodulator | Phase 1 |
| AC Immune | Semorinemab | Tau | Anti-tau antibody | Phase 2 |
| Vaccinex | Pepinemab | SEMA4D | Immunomodulation | Phase 2 |
Vaccinex Differentiation:
Competitive Challenges:
Vaccinex is publicly traded on NASDAQ under the ticker symbol VCNX. The company has focused its resources on advancing its clinical and preclinical programs in both neurodegeneration and oncology.
Key Financial Metrics:
December 2025 Financing:
In December 2025, Vaccinex announced a significant $60 million financing agreement specifically allocated to fund a Phase 2b clinical trial of pepinemab for Alzheimer's disease. This represents a major validation of the company's SEMA4D targeting approach and provides runway for advanced clinical development.
Vaccinex's approach to targeting neuroinflammation through SEMA4D represents an alternative mechanism to more traditional amyloid and tau-targeted approaches in Alzheimer's disease. The company's focus on modulating immune cell signaling provides insights into the role of neuroinflammation in Parkinson's disease progression.
The rationale for targeting SEMA4D in neurodegenerative diseases stems from its central role in coordinating neuroinflammatory responses:
Microglial Activation:
SEMA4D is a key regulator of microglial activation states. In the healthy brain, microglia exist in a surveillance mode, continuously scanning their environment. In neurodegenerative conditions, SEMA4D signaling promotes transition to an activated, pro-inflammatory phenotype characterized by increased cytokine production, phagocytic activity, and potential neurotoxicity. Blocking SEMA4D can shift microglia toward a more protective, anti-inflammatory state.
Neuroinflammation Cascade:
SEMA4D orchestrates a cascade of inflammatory events in the CNS. When SEMA4D binds to its receptors (Plexin-B1 on neurons and oligodendrocytes, CD72 on immune cells), it triggers downstream signaling that amplifies production of pro-inflammatory cytokines including IL-1β, TNF-α, and IL-6. This creates a self-perpetuating cycle of neuroinflammation that drives disease progression.
Oligodendrocyte Function:
SEMA4D inhibits oligodendrocyte precursor cell (OPC) differentiation and myelination. In conditions like multiple system atrophy (MSA) and potentially AD, this contributes to white matter damage and neuronal connectivity deficits. SEMA4D blockade may support remyelination and white matter integrity.
Targeting SEMA4D offers several potential advantages over other therapeutic approaches:
Disease-Modifying Potential: By addressing neuroinflammation as an upstream driver of neurodegeneration, SEMA4D inhibition may slow disease progression rather than just treating symptoms.
Broad Applicability: Neuroinflammation is a common feature across multiple neurodegenerative conditions, suggesting SEMA4D-targeted therapies could have applications in AD, PD, HD, MSA, and ALS.
Complementary Mechanism: SEMA4D inhibition could potentially be combined with amyloid-targeted, tau-targeted, or other mechanisms for synergistic effects.
Peripheral Administration: As a monoclonal antibody, pepinemab can be administered intravenously, avoiding the need for direct CNS delivery.
| Approach | Target | Company | Status |
|---|---|---|---|
| Anti-SEMA4D | SEMA4D | Vaccinex | Phase 2 |
| Anti-TREM2 | TREM2 | Various | Preclinical |
| Anti-CD47 | CD47 | Checkpoint inhibitors | Oncology |
| CSF1R inhibitors | CSF1R | Various | Phase 1/2 |
| NLRP3 inhibitors | NLRP3 inflammasome | Various | Preclinical |
Each approach targets different aspects of neuroinflammation. SEMA4D inhibition represents a distinct mechanism affecting both innate immune cell trafficking and activation.
The global Alzheimer's disease therapeutic market represents one of the largest opportunities in pharmaceutical development:
The recent approvals of Leqembi (lecanemab) and donanemab have validated the amyloid-targeting approach and created a pathway for other disease-modifying therapies. However, significant opportunity remains for mechanisms addressing neuroinflammation, particularly for patients who cannot access or do not respond to anti-amyloid therapies.
Neuroinflammation is increasingly recognized as a key contributor to PD progression. While Vaccinex's PD program is not currently active, the mechanism remains scientifically relevant for future development.
The SIGNAL trial in HD demonstrated feasibility of SEMA4D targeting in neurodegeneration and provided safety data supporting continued development.
Vaccinex operates through a combination of internal capabilities and contract manufacturing organizations (CMOs):
Current Manufacturing:
Future Requirements:
Headquarters: Rochester, New York, USA
Employees: Approximately 50-100 employees
Operations: Focus on clinical development, with external manufacturing and administrative support
The company leverages a virtual, asset-light operational model typical of clinical-stage biotechnology companies, minimizing fixed costs while maintaining core competencies in research and clinical development.
Vaccinex aims to establish SEMA4D inhibition as a validated therapeutic approach for neurodegenerative diseases. The company's dual-focus strategy on both neurology and oncology provides operational flexibility and multiple shots on goal. With the December 2025 financing in place, the company is positioned to execute on its Phase 2b Alzheimer's trial and potentially expand into additional indications.